Education

M.D., Medicine, University of Rochester School of Medicine, NY

Ph.D., Microbiology and Immunology, University of Rochester School of Medicine, NY


Training

Dr. Zambidis earned his M.D./Ph.D. in the Medical Scientist Training Program at the University of Rochester School of Medicine, Rochester, N.Y. He did his Pediatrics Residency in the Department of Pediatrics, Washington University, St. Louis, Missouri, and his clinical/research fellowship in Pediatric Hematology/Oncology at the Johns Hopkins Hospital, Baltimore, MD and the National Cancer Institute at the NIH. He has been on the Oncology and Pediatrics faculty at the Johns Hopkins School of Medicine since 2005.


Certifications

American Board of Pediatrics

American Association of Pediatrics

American Society of Hematology


Clinical Expertise

Pediatric oncology specializing in hematologic malignancies, blood and bone marrow transplantation (BMT), stem cell biology and therapeutics, and immune system engineering.   


Research Summary

Dr. Zambidis is interested in the developmental biology of normal and malignant hematopoietic stem cells. His group employs genetic manipulation and differentiation of human embryonic and induced pluripotent stem cells (iPSC) to study the cellular and molecular mechanisms of human hematopoiesis. Using human embryonic stem cells (hESC) derived from both normal and preimplantation genetic diagnosis (PGD)-screened embryos, as well as human iPSC, he is exploring how early mesodermal progenitors and human hemangioblast (bi-potential progenitor of hematopoietic stem cells (HSC) and endothelium) may give rise to the entire human hematopoietic  and vascular systems, and whether such progenitors can be derived and expanded from differentiating human iPSC. His laboratory is studying the role of a variety of proteins and signaling molecules that are critically important in orchestrating the initiation of human embryonic hematopoiesis by directing the formation of human hemato-vascular progenitors in hESC and hiPSC. hESC/hiPSC-derived blood progenitors are also important in the understanding of the developmental origins of pediatric leukemia, but also for clinical HSC transplantation. A major area of focus is determining the shared molecular circuits that regulate both malignant transformation and the maintenance of pluripotency. Applying these principles of shared biology between hematopoietic stem-progenitors and pluripotent stem cells, his group recently accomplished the creation of improved, highly efficient methods for generating nonintegrated, non-viral human induced pluripotent stem cell (hiPSC) lines from myeloid progenitors that possess enhanced differentiation capacities and rapid loss of epigenetic memory.



Publications


 

Elias Zambidis, MD/PhD


Principal Investigator

Associate Professor in Oncology and Pediatrics

Sidney Kimmel Comprehensive Cancer Center

Institute for Cell Engineering


Email: ezambid1@jhmi.edu



Copyright The Johns Hopkins University 2013